CLUH

Summary

CLUH (CLUH binding protein of NUMT mRNA, HGNC:29094) is a protein-coding gene on chromosome 17p13.3, encoding Clustered mitochondria protein homolog (O75153). mRNA-binding protein involved in proper cytoplasmic distribution of mitochondria.

Enables mRNA binding activity. Involved in intracellular distribution of mitochondria and mitochondrion organization. Located in cytoplasm.

Source: NCBI Gene 23277 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 278 total — 13 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 2
• Druggable target: yes
• MANE Select transcript: NM_001366661

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29094
Approved symbol	CLUH
Name	CLUH binding protein of NUMT mRNA
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Aliases	CLU1
Ensembl gene	ENSG00000132361
Ensembl biotype	protein_coding
OMIM	616184
Entrez	23277

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 15 protein_coding, 6 retained_intron

ENST00000435359, ENST00000570628, ENST00000571539, ENST00000571566, ENST00000572014, ENST00000572129, ENST00000573641, ENST00000574166, ENST00000574210, ENST00000574426, ENST00000575014, ENST00000575624, ENST00000576309, ENST00000576885, ENST00000651024, ENST00000876316, ENST00000876317, ENST00000876318, ENST00000923739, ENST00000923740, ENST00000923741

RefSeq mRNA: 3 — MANE Select: NM_001366661 NM_001366661, NM_001366662, NM_015229

CCDS: CCDS92220, CCDS92221

Canonical transcript exons

ENST00000651024 — 26 exons

Exon	Start	End
ENSE00001366494	2703318	2703489
ENSE00002669334	2696434	2696538
ENSE00002816737	2701914	2702057
ENSE00002833477	2701140	2701265
ENSE00002855086	2696719	2696942
ENSE00002864489	2700678	2700825
ENSE00002881265	2701613	2701737
ENSE00002893827	2701366	2701520
ENSE00002898043	2697896	2698590
ENSE00002945069	2695374	2695526
ENSE00003469679	2704362	2704564
ENSE00003673816	2700382	2700474
ENSE00003703112	2694480	2694564
ENSE00003704702	2692571	2692696
ENSE00003705157	2694857	2695101
ENSE00003705658	2692004	2692097
ENSE00003705813	2692780	2692860
ENSE00003705848	2692361	2692482
ENSE00003707007	2693900	2694039
ENSE00003707849	2691761	2691895
ENSE00003709142	2694123	2694276
ENSE00003709831	2696159	2696259
ENSE00003710689	2695218	2695280
ENSE00003788174	2691609	2691682
ENSE00003844173	2711562	2711764
ENSE00003845280	2689387	2690777

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 97.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.7067 / max 281.5528, expressed in 1814 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163837	28.3855	1810
163836	8.2526	1730
163834	0.0687	24

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	97.74	gold quality
apex of heart	UBERON:0002098	97.66	gold quality
right lobe of liver	UBERON:0001114	97.60	gold quality
mucosa of transverse colon	UBERON:0004991	97.18	gold quality
gastrocnemius	UBERON:0001388	97.10	gold quality
lower esophagus mucosa	UBERON:0035834	96.58	gold quality
esophagus mucosa	UBERON:0002469	96.43	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.41	gold quality
heart left ventricle	UBERON:0002084	96.19	gold quality
muscle of leg	UBERON:0001383	96.16	gold quality
transverse colon	UBERON:0001157	96.11	gold quality
cardiac ventricle	UBERON:0002082	96.11	gold quality
left adrenal gland cortex	UBERON:0035825	96.10	gold quality
left adrenal gland	UBERON:0001234	96.01	gold quality
right adrenal gland	UBERON:0001233	95.93	gold quality
adrenal cortex	UBERON:0001235	95.86	gold quality
metanephros cortex	UBERON:0010533	95.76	gold quality
liver	UBERON:0002107	95.66	gold quality
right adrenal gland cortex	UBERON:0035827	95.59	gold quality
skin of leg	UBERON:0001511	95.49	gold quality
muscle organ	UBERON:0001630	95.41	gold quality
body of tongue	UBERON:0011876	95.40	gold quality
right atrium auricular region	UBERON:0006631	95.36	gold quality
skin of abdomen	UBERON:0001416	95.29	gold quality
adrenal gland	UBERON:0002369	95.28	gold quality
body of pancreas	UBERON:0001150	95.27	gold quality
cardiac atrium	UBERON:0002081	95.01	gold quality
gingiva	UBERON:0001828	94.87	gold quality
pharyngeal mucosa	UBERON:0000355	94.78	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.66	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.82
E-CURD-53	no	385.19
E-MTAB-9689	no	136.75

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

64 targeting CLUH, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-92A-2-5P	99.75	67.01	2164

Literature-anchored findings (GeneRIF, showing 4)

• Here, the authors show that CLUH, a host protein whose cellular function is not well established, plays a key role in the subnuclear transport of influenza virus nucleoprotein. (PMID:27573102)
• CLUH couples mitochondrial distribution to the energetic and metabolic status. (PMID:28424233)
• CLUH granules coordinate translation of mitochondrial proteins with mTORC1 signaling and mitophagy. (PMID:32149416)
• CLUH functions as a negative regulator of inflammation in human macrophages and determines ulcerative colitis pathogenesis. (PMID:37140992)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cluha	ENSDARG00000030913
danio_rerio	cluhb	ENSDARG00000060566
mus_musculus	Cluh	ENSMUSG00000020741
rattus_norvegicus	Cluh	ENSRNOG00000002669
drosophila_melanogaster	clu	FBGN0034087
caenorhabditis_elegans		WBGENE00000550

Protein

Protein identifiers

Clustered mitochondria protein homolog — O75153 (reviewed: O75153)

All UniProt accessions (8): O75153, A0A494C0R8, I3L2B0, I3L318, I3L350, I3L3A3, I3L4B5, K7EIG1

UniProt curated annotations — full annotation on UniProt →

Function. mRNA-binding protein involved in proper cytoplasmic distribution of mitochondria. Specifically binds mRNAs of nuclear-encoded mitochondrial proteins in the cytoplasm and regulates transport or translation of these transcripts close to mitochondria, playing a role in mitochondrial biogenesis.

Subcellular location. Cytoplasm. Cytoplasmic granule.

Similarity. Belongs to the CLU family.

RefSeq proteins (3): NP_001353590, NP_001353591, NP_056044 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR023231	GSKIP_dom_sf	Homologous_superfamily
IPR025697	CLU_dom	Domain
IPR027523	CLU_prot	Family
IPR028275	CLU_N	Domain
IPR033646	CLU-central	Domain

Pfam: PF12807, PF13236, PF13424, PF15044

UniProt features (27 total): sequence conflict 8, modified residue 5, compositionally biased region 4, repeat 4, region of interest 3, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75153-F1	83.11	0.59

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 279, 281, 654, 664, 723

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (3): mitochondrion organization (GO:0007005), intracellular distribution of mitochondria (GO:0048312), organelle organization (GO:0006996)

GO Molecular Function (3): mRNA binding (GO:0003729), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organelle organization	1
mitochondrion distribution	1
cellular component organization	1
RNA binding	1
nucleic acid binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1558 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLUH	FAHD1	Q6P587	608
CLUH	G3BP2	Q9UN86	587
CLUH	COQ6	Q9Y2Z9	498
CLUH	CPT2	P23786	487
CLUH	DRC7	Q8IY82	465
CLUH	COQ3	Q9NZJ6	452
CLUH	CFAP45	Q9UL16	445
CLUH	TOMM20	Q15388	439
CLUH	EIF3G	O75821	415
CLUH	PPTC7	Q8NI37	414
CLUH	SERPINB1	P30740	414
CLUH	PRKN	O60260	406
CLUH	EIF5	P55010	396
CLUH	ZC3H10	Q96K80	389
CLUH	DLG3	Q92796	387

IntAct

117 interactions, top by confidence:

A	B	Type	Score
ARPC3	ARPC1B	psi-mi:“MI:0914”(association)	0.880
FECH	PGRMC1	psi-mi:“MI:0914”(association)	0.700
MPPED1	TXNDC9	psi-mi:“MI:0914”(association)	0.640
ARPC3	ARPC2	psi-mi:“MI:0914”(association)	0.640
HDAC11	CLUH	psi-mi:“MI:0914”(association)	0.640
MPPED1	CLUH	psi-mi:“MI:0914”(association)	0.640
IFT57	IFT56	psi-mi:“MI:0914”(association)	0.640
COA8	CLUH	psi-mi:“MI:0915”(physical association)	0.590
TRAPPC2L	TRAPPC13	psi-mi:“MI:0914”(association)	0.560
WDR37	CLUH	psi-mi:“MI:0914”(association)	0.530
MOS	CLUH	psi-mi:“MI:0914”(association)	0.530
PMPCA	CLUH	psi-mi:“MI:0914”(association)	0.530
DCAF4L2	CLUH	psi-mi:“MI:0914”(association)	0.530
DCAF4	CLUH	psi-mi:“MI:0914”(association)	0.530
THOC3	CLUH	psi-mi:“MI:0914”(association)	0.530
TEKT3	CLUH	psi-mi:“MI:0914”(association)	0.530
PINK1	CLUH	psi-mi:“MI:0914”(association)	0.530
ZAR1L	BCL2L11	psi-mi:“MI:0914”(association)	0.530
NIPSNAP3A	CLUH	psi-mi:“MI:0914”(association)	0.530

BioGRID (200): CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), CLUH (Affinity Capture-MS), ABCF2 (Co-fractionation), CLUH (Co-fractionation), CLUH (Co-fractionation), DYNC1LI1 (Co-fractionation), DYNC1LI2 (Co-fractionation)

ESM2 similar proteins: A0JMD0, A1A535, A1ZAB5, A2AIV2, A8E7C5, A8PJX4, A8XAA9, B0W2S0, B3MIW0, B3NPV8, B4GAM1, B4JW99, B4KT50, B4LQ23, B4MY63, B4P6P7, D3YVL2, E9PXF8, F4HS99, F4HZK4, F4J5S1, F4JKH6, O60502, O75153, O88379, P34466, P69735, Q0IHW8, Q0VA04, Q15042, Q17N71, Q291J5, Q5PQS3, Q5SW19, Q5TYW4, Q5U430, Q69YN4, Q6NTN5, Q6ZT12, Q7PZD5

Diamond homologs: A0JMD0, A1ZAB5, A8PJX4, A8XAA9, B0W2S0, B3MIW0, B3NPV8, B4GAM1, B4JW99, B4KT50, B4LQ23, B4MY63, B4P6P7, O75153, P0C7X3, P34466, Q0IHW8, Q17N71, Q291J5, Q5SW19, Q7PZD5, A1CKI4, A1D6Y7, A2QDB9, A3GG12, A4R962, A5DLU8, A5DWP3, A6R8I2, A6SFG0, A7ENU3, A8QA64, B0XXS1, B5RSP9, O59742, P0CR86, P0CR87, Q0CNX5, Q0U0H7, Q1E101

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

278 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	13
Likely pathogenic	2
Uncertain significance	208
Likely benign	12
Benign	6

Top pathogenic / likely-pathogenic (15)

Variant ID	HGVS	Classification
1403973	NC_000017.10:g.(?2541583)(3819519_?)del	Pathogenic
1807811	GRCh37/hg19 17p13.3(chr17:2161424-2825460)x1	Pathogenic
253440	GRCh37/hg19 17p13.3(chr17:1218064-2619473)x1	Pathogenic
3063527	GRCh37/hg19 17p13.3(chr17:1505119-3010963)x1	Pathogenic
394497	GRCh37/hg19 17p13.3(chr17:1936753-2901448)x1	Pathogenic
4083495	GRCh37/hg19 17p13.3(chr17:2568666-2598574)x1	Pathogenic
4279136	GRCh37/hg19 17p13.3(chr17:2388126-2886447)x1	Pathogenic
4279416	GRCh37/hg19 17p13.3-13.2(chr17:2402229-3322885)x1	Pathogenic
443283	GRCh37/hg19 17p13.3(chr17:1997443-2825460)x1	Pathogenic
4682911	GRCh37/hg19 17p13.3(chr17:2316531-2972634)x1	Pathogenic
523261	GRCh37/hg19 17p13.3(chr17:2339561-2826073)	Pathogenic
686828	GRCh37/hg19 17p13.3(chr17:2172709-2646895)x1	Pathogenic
687701	GRCh37/hg19 17p13.3(chr17:1501331-2832123)x3	Pathogenic
442715	GRCh37/hg19 17p13.3(chr17:2213316-2901583)x3	Likely pathogenic
983494	NC_000017.11:g.2688360_2784321del	Likely pathogenic

SpliceAI

3864 predictions. Top by Δscore:

Variant	Effect	Δscore
17:2691603:CCTCA:C	donor_loss	1.0000
17:2691606:CACCT:C	donor_loss	1.0000
17:2691607:A:C	donor_loss	1.0000
17:2691608:C:A	donor_loss	1.0000
17:2691679:TGAA:T	acceptor_gain	1.0000
17:2691682:AC:A	acceptor_loss	1.0000
17:2691683:C:CC	acceptor_gain	1.0000
17:2691684:T:G	acceptor_loss	1.0000
17:2691756:CTCA:C	donor_loss	1.0000
17:2691757:TCA:T	donor_loss	1.0000
17:2691758:CACCT:C	donor_loss	1.0000
17:2691759:A:AC	donor_gain	1.0000
17:2691759:ACCT:A	donor_loss	1.0000
17:2691760:C:CC	donor_gain	1.0000
17:2691891:CCCAG:C	acceptor_gain	1.0000
17:2691892:CCAG:C	acceptor_gain	1.0000
17:2691892:CCAGC:C	acceptor_gain	1.0000
17:2691893:CAG:C	acceptor_gain	1.0000
17:2691893:CAGC:C	acceptor_gain	1.0000
17:2691894:AG:A	acceptor_gain	1.0000
17:2691894:AGC:A	acceptor_loss	1.0000
17:2691896:C:CC	acceptor_gain	1.0000
17:2691896:CT:C	acceptor_loss	1.0000
17:2691899:C:CT	acceptor_gain	1.0000
17:2691900:G:T	acceptor_gain	1.0000
17:2691999:CGCA:C	donor_loss	1.0000
17:2692000:GCAC:G	donor_loss	1.0000
17:2692001:CA:C	donor_loss	1.0000
17:2692002:A:AT	donor_loss	1.0000
17:2692003:CCTG:C	donor_gain	1.0000

AlphaMissense

8868 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:2691645:A:G	L1237P	1.000
17:2691816:C:G	R1206P	1.000
17:2691822:A:G	L1204P	1.000
17:2691831:G:T	A1201D	1.000
17:2691843:A:G	L1197P	1.000
17:2691852:A:G	L1194P	1.000
17:2692044:A:G	L1166P	1.000
17:2692047:G:T	A1165D	1.000
17:2692055:G:C	F1162L	1.000
17:2692055:G:T	F1162L	1.000
17:2692057:A:G	F1162L	1.000
17:2692083:G:T	A1153D	1.000
17:2692463:A:G	L1114P	1.000
17:2692472:C:T	G1111E	1.000
17:2692473:C:A	G1111W	1.000
17:2694144:C:A	G985W	1.000
17:2698064:C:G	R560P	1.000
17:2698065:G:T	R560S	1.000
17:2698070:T:A	D558V	1.000
17:2698070:T:G	D558A	1.000
17:2698071:C:G	D558H	1.000
17:2698076:C:A	G556V	1.000
17:2698076:C:T	G556D	1.000
17:2698077:C:G	G556R	1.000
17:2698082:A:C	I554S	1.000
17:2698082:A:G	I554T	1.000
17:2698082:A:T	I554N	1.000
17:2698085:C:T	G553D	1.000
17:2698086:C:G	G553R	1.000
17:2698087:C:A	K552N	1.000

dbSNP variants (sampled 300 via entrez): RS1000035942 (17:2713393 G>A), RS1000085486 (17:2707903 C>T), RS1000086913 (17:2704321 A>C,G), RS1000138141 (17:2708028 C>T), RS1000544959 (17:2692257 T>C,G), RS1000636047 (17:2695886 C>G,T), RS1000664700 (17:2690832 C>T), RS1000686102 (17:2696346 GA>G), RS1000688344 (17:2709264 G>A), RS1000721546 (17:2691062 C>A,G,T), RS1000857023 (17:2700568 C>G), RS1000973148 (17:2703216 C>T), RS1001014981 (17:2705186 G>A), RS1001026488 (17:2698635 G>A,C), RS1001075553 (17:2698712 C>G,T)

Disease associations

OMIM: gene MIM:616184 | disease phenotypes: MIM:142623, MIM:607432, MIM:615656

GenCC curated gene-disease

Mondo (7): Hirschsprung disease, susceptibility to, 1 (MONDO:0007723), lissencephaly due to LIS1 mutation (MONDO:0011830), microcephaly (MONDO:0001149), strabismus (MONDO:0003432), pathologic nystagmus (MONDO:0004843), lissencephaly spectrum disorders (MONDO:0018838), chromosome 15q11.2 deletion syndrome (MONDO:0014294)

Orphanet (4): Hirschsprung disease (Orphanet:388), Lissencephaly due to LIS1 mutation (Orphanet:95232), Lissencephaly (Orphanet:48471), 15q11.2 microdeletion syndrome (Orphanet:261183)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly
HP:0001339	Lissencephaly

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002404_347	Red cell distribution width	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009188	Red cell distribution width

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D054082	Lissencephaly	C10.500.507.450.499; C16.131.666.507.450.499
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D009759	Nystagmus, Pathologic	C10.292.562.675; C11.590.400
D013285	Strabismus	C10.292.562.887; C11.590.810

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295673 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	4
perfluoro-n-nonanoic acid	decreases expression	2
Acetaminophen	decreases expression	2
Estradiol	increases expression	2
Valproic Acid	affects expression, increases expression	2
dicrotophos	increases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	affects cotreatment, decreases methylation	1
beta-lapachone	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	increases expression	1
methacrylaldehyde	decreases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
NSC 689534	decreases expression, affects binding	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acrolein	increases abundance, affects cotreatment, decreases expression	1
Air Pollutants	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118616	Binding	Binding affinity to CLUH in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2UI	Abcam HEK293T CLUH KO	Transformed cell line	Female

Clinical trials (associated diseases)

167 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02343562	PHASE4	UNKNOWN	Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis
NCT07186647	PHASE4	COMPLETED	Laparoscopic-Assisted Transanal Pull-Through for Hirschsprung Disease in Pediatric:Short and Intermediate Outcomes of Two Different Techniques
NCT00461656	PHASE4	COMPLETED	Povidone-iodine Antisepsis for Strabismus Surgery
NCT01901588	PHASE4	COMPLETED	Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT02379546	PHASE4	COMPLETED	The Effect of Anaesthesia Depth on Oculo-cardiac Reflex
NCT03349515	PHASE4	COMPLETED	The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.
NCT04549844	PHASE4	UNKNOWN	Peribulbar Block for Prevention of Oculocardiac Reflex
NCT06035757	PHASE4	RECRUITING	The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
NCT06560268	PHASE4	NOT_YET_RECRUITING	Low Flow Anesthesia in Children Undergoing Strabismus Surgery
NCT04904081	PHASE3	UNKNOWN	Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery
NCT00000128	PHASE3	UNKNOWN	A Trial of Bifocals in Myopic Children With Esophoria
NCT00001864	PHASE3	COMPLETED	Amblyopia (Lazy Eye) Treatment Study
NCT00038753	PHASE3	UNKNOWN	Vision In Preschoolers Study (VIP Study)
NCT01584843	PHASE3	COMPLETED	Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
NCT04060771	PHASE3	UNKNOWN	Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
NCT06863675	PHASE3	NOT_YET_RECRUITING	Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]
NCT00630838	PHASE2	COMPLETED	Probiotic Prophylaxis of Hirschprung’s Disease Associated Enterocolitis (HAEC)
NCT00478907	PHASE2	COMPLETED	Prevention of Complications of Eye Surgery
NCT06689943	PHASE2	NOT_YET_RECRUITING	Pain After Strabismus Surgery
NCT00917982	PHASE1	UNKNOWN	The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients
NCT02246556	PHASE1	TERMINATED	Dichoptic Virtual Reality Therapy for Amblyopia in Adults
NCT01985646	EARLY_PHASE1	COMPLETED	A Trial on Conservative Treatment for Infants’ Hirschsprung Disease
NCT00478712	Not specified	RECRUITING	Hirschsprung Disease Genetic Study
NCT01515501	Not specified	COMPLETED	Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT01927809	Not specified	UNKNOWN	Genetic Mosaicism in Hirschsprung’s Disease
NCT02193685	Not specified	UNKNOWN	Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease
NCT02216994	Not specified	UNKNOWN	A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis –a Prospective Study
NCT02296008	Not specified	COMPLETED	3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders
NCT02776176	Not specified	UNKNOWN	Enhanced Recovery After Surgery In Hirschsprung Disease
NCT02857205	Not specified	COMPLETED	MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung’s Associated EnteroColitis
NCT03269812	Not specified	UNKNOWN	Laparoscopic Assisted Pull-through Versus Other Surgical Procedures for Treatment of Hirschsprung Disease
NCT03666767	Not specified	COMPLETED	Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries
NCT04020939	Not specified	COMPLETED	The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.
NCT04106947	Not specified	UNKNOWN	Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations
NCT04149093	Not specified	UNKNOWN	The Association Between Calretinin and the Function of Ganglion Cells in Hirschsprung Disease
NCT04150120	Not specified	COMPLETED	eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness
NCT04213976	Not specified	UNKNOWN	Ostomy in Continuity or Conventional Ileostomy: a Retrospective Multicentric Analysis
NCT04476225	Not specified	COMPLETED	Induced Pluripotent Stem Cells for Disease Research
NCT04598841	Not specified	COMPLETED	Nutrition Support for Hirschsprung Disease